CMS accepted a request from Edwards Lifesciences for a new coverage determination (NCD) for transcatheter aortic valve ...

Medicare reimbursement for aortic stenosis patients without symptoms could accelerate procedure growth for Edwards Lifesciences, which requested the CMS review, analysts said.

Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

Atlanta — A randomized transcatheter aortic valve replacement (TAVR) trial demonstrated that a self-expanding device performs better on multiple prognostically important measures of valve function at ...

A US Food and Drug Administration (FDA) advisory panel struggled to muster support for marketing clearance of the TriGuard 3 (Keystone Heart) device for use during transcatheter aortic valve ...

Stroke remains a problem after TAVR and continues to feed discussions around how extensively cerebral embolic protection devices and other strategies should be used. In a session during TVT Connect, ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

Emerging data for two latest-generation transcatheter aortic valve prostheses in the setting of failed surgical valves are “reassuring,” according to late-breaking clinical science presentations at ...

CHICAGO -- Tweaks made to Medtronic's CoreValve transcatheter heart valve (THV) line in the last few years have tracked with some improved outcomes after transcatheter aortic valve replacement (TAVR), ...

ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

(Reuters) - Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices. The ...